Consensus statement on research definitions for drug-resistant tuberculosis in children

Journal of the Pediatric Infectious Diseases Society

Volumn 2, Issue 2, 2013, Pages 100-109

  Seddon, James A ^a,b   Perez Velez, Carlos M ^c   Schaaf, H Simon ^a,d   Furin, Jennifer J ^e   Marais, Ben J ^f   Tebruegge, Marc ^g,h,i   Detjen, Anne ^j   Hesseling, Anneke C ^a   Shah, Sarita ^k   Adams, Lisa V ^l   Starke, Jeffrey R ^m   Swaminathan, Soumya ⁿ   Becerra, Mercedes C ^o,p  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c UNIVERSIDAD DE ANTIOQUIA   (Colombia)

^d STELLENBOSCH UNIVERSITY   (South Africa)

^e CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF SYDNEY   (Australia)

^g Faculty of Medicine   (United Kingdom)

^h UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

ⁱ UNIVERSITY OF MELBOURNE   (Australia)

^j INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (United States)

^k ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^l DARTMOUTH MEDICAL SCHOOL   (United States)

^m BAYLOR COLLEGE OF MEDICINE   (United States)

ⁿ NATIONAL INSTITUTE FOR RESEARCH IN TUBERCULOSIS   (India)

^o HARVARD MEDICAL SCHOOL   (United States)

^p PARTNERS IN HEALTH   (United States)

more..

Author keywords

Children; Consensus; Definition; Drug Resistance; Pediatric; Tuberculosis

Indexed keywords

ARTICLE; CONSENSUS DEVELOPMENT; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG RESISTANCE; DRUG RESISTANT TUBERCULOSIS; HUMAN; MEDICAL RESEARCH; MEDICAL TERMINOLOGY; METHODOLOGY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 84898902322     PISSN: 20487193     EISSN: 20487207     Source Type: Journal    
DOI: 10.1093/jpids/pit012     Document Type: Article

References (54)

1. World Health Organization, Geneva, Switzerland. Global tuberculosis control. WHO/HTM/TB/201116 2011. Available at: http://www.who.int/tb/publications/global_report/2011/gtbr11_full.pdf. Accessed March 26, 2013.
2. World Health Organization, Geneva, Switzerland. Guidelines for the programmatic management of drug-resistant tuberculosis - Emergency update. WHO/HTM/TB/2008402 2008. Available at: http://whqlibdoc.who.int/publications/2008/9789241547581_ eng.pdf. AccessedMarch 26, 2013.
3. Marais BJ, Hesseling AC, Gie RP, et al. The burden of childhood tuberculosis and the accuracy of community-based surveillance data. Int J Tuberc Lung Dis 2006; 10:259-63.
4. van Rie A, Beyers N, Gie RP, et al. Childhood tuberculosis in an urban population in South Africa: burden and risk factor. Arch Dis Child 1999; 80:433-7.
5. Marais BJ, Schaaf HS. Childhood tuberculosis: an emerging and previously neglected problem. Infect Dis Clin North Am 2010; 24:727-49.
6. Ettehad D, Schaaf HS, Seddon JA, et al. Treatment outcomes for children with multidrug-resistant tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12:449-56.
7. World Health Organization, Geneva, Switzerland. Roadmap for rolling out Xpert MTB/RIF for rapid diagnosis of TB and MDR-TB. Available at: http://www.who.int/tb/laboratory/roadmap_xpert_mtb_rif.pdf. Accessed March 26, 2013.
8. World Health Organization, Geneva, Switzerland. Molecular line probe assays for the rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB). Policy Statement. 2008: Available at: http://www.who.int/tb/features_archive/policy_statement.pdf. Accessed March 26, 2013.
9. The Sentinel Project on Pediatric Drug-Resistant Tuberculosis. Available at: www.sentinel-project.org. Accessed March 26, 2013.
10. Rieder HL. Epidemiologic Basis of Tuberculosis Control. 1st ed. International Union Against Tuberculosis and Lung Disease. Paris, France; 1999.
11. Mandalakas AM, Kirchner HL, Lombard C, et al. Well-quantified tuberculosis exposure is a reliable surrogate measure of tuberculosis infection. Int J Tuberc Lung Dis 2012; 16:1033-9.
12. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis. A general review. Bibl Tuberc 1970; 26:28-106.
13. Davies PD. The natural history of tuberculosis in children. A study of child contacts in the Brompton Hospital Child Contact Clinic from 1930 to 1952. Tubercle 1961; 42(Suppl):1-40.
14. Gedde-Dahl T. Tuberculous infection in the light of tuberculin matriculation. Am J Hyg 1952; 56:139-214.
15. Marais BJ, Gie RP, Schaaf HS, et al. The natural history of childhood intra-thoracic tuberculosis: a critical review of literature from the pre-chemotherapy era. Int J Tuberc Lung Dis 2004; 8: 392-402.
16. Van Wyk SS, Mandalakas AM, Enarson DA, et al. Tuberculosis contact investigation in a high-burden setting: house or household? Int J Tuberc Lung Dis 2012; 16:157-62.
17. Lin PL, Flynn JL. Understanding latent tuberculosis: a moving target. J Immunol 2010; 185:15-22.
18. Graham SM, Ahmed T, Amanullah F, et al. Evaluation of tuberculosis diagnostics in children: 1. Proposed clinical case definitions for classification of intrathoracic tuberculosis disease. Consensus from an expert panel. J Infect Dis 2012; 205(Suppl 2):S199-208.
19. Clinical and Laboratory Standards Institute (CLSI). Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes; Approved Standard - Second Edition: CLSI document M24-A2 (ISBN 1-56238-746-4). Clinical and Laboratory Standards Insitutue,Wayne, PA.
20. Perez-Velez CM, Marais BJ. Tuberculosis in children. N Engl J Med 2012; 367:348-61.
21. Mukinda FK, Theron D, van der Spuy GD, et al. Rise in rifampicin-monoresistant tuberculosis in Western Cape, South Africa. Int J Tuberc Lung Dis 2012; 16:196-202.
22. Hazbon MH, Brimacombe M, del Valle M Bobadilla, et al. Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 2006; 50:2640-9.
23. Muller B, Streicher EM, Hoek KG, et al. inhA promoter mutations: a gateway to extensively drug-resistant tuberculosis in South Africa? Int J Tuberc Lung Dis 2011; 15:344-51.
24. Sandgren A, Strong M, Muthukrishnan P, et al. Tuberculosis drug resistance mutation database. PLoSMed 2009; 6:e2.
25. World Health Organization, Geneva, Switzerland. Provisional guidelines for the diagnosis and classification of the EPI target diseases for primary health care, surveillance and special studies. EPI/GEN/83/4 1986. Available at: http://whqlibdoc.who.int/euro/-1993/ICP_EPI_012_12.pdf. Accessed March 26, 2013.
26. Marais S, Thwaites G, Schoeman JF, et al. Tuberculous meningitis: a uniform case definition for use in clinical research. Lancet Infect Dis 2010; 10:803-12.
27. Seddon JA, Hesseling AC, Willemse M, et al. Culture-confirmed multidrug-resistant tuberculosis in children: clinical features, treatment, and outcome. Clin Infect Dis 2012; 54:157-66.
28. Schaaf HS, Marais BJ, Hesseling AC, et al. Surveillance of antituberculosis drug resistance among children from the Western Cape Province of South Africa-an upward trend. Am J Public Health 2009; 99:1486-90.
29. Wiseman CA, Gie RP, Starke JR, et al. A proposed comprehensive classification of tuberculosis disease severity in children. Pediatr Infect Dis J 2012; 31:347-52.
30. Marais BJ, Hesseling AC, Gie RP, et al. The bacteriologic yield in children with intrathoracic tuberculosis. Clin Infect Dis 2006; 42:e69-71.
31. World Health Organization, Geneva, Switzerland. International Statistical Classification of Diseases and Related Health Problems. 10th Revision. Available at: http://apps.who.int/classifications/icd10/browse/2010/en. Accessed March 26, 2013.
32. Marais BJ, Gie RP, Schaaf HS, et al. A proposed radiological classification of childhood intra-thoracic tuberculosis. Pediatr Radiol 2004; 34:886-94.
33. Bloss E, Kuksa L, Holtz TH, et al. Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000-2004. Int J Tuberc Lung Dis 2010; 14:275-81.
34. Papastavros T, Dolovich LR, Holbrook A, et al. Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis. CMAJ 2002; 167:131-6.
35. Division of Microbiology and Infectious Diseases. Pediatric Toxicity Tables. November 2007 DRAFT. Available at: http://www.niaid.nih.gov/LabsAndResources/resources/DMIDClinRsrch/Documents/dmidpedtox.pdf. Accessed March 26, 2013.
36. Drobac PC, Mukherjee JS, Joseph JK, et al. Community-based therapy for children with multidrug-resistant tuberculosis. Pediatrics 2006; 117:2022-9.
37. Marra F, Marra CA, Moadebi S, et al. Levofloxacin treatment of active tuberculosis and the risk of adverse events. Chest 2005; 128:1406-13.
38. Laserson KF, Thorpe LE, Leimane V, et al. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2005; 9:640-5.
39. World Health Organization, Geneva, Switzerland. Guidance for National Tuberculosis Programmes on the management of tuberculosis in children. WHO/HTM/TB/2006371, WHO/FCH/CAH/20067 2006. Available at: http://www.who.int/maternal_child_adolescent/documents/htm_tb_2006_371/en/index.html. Accessed March 26, 2013.
40. Starke JR. Pediatric tuberculosis: time for a new approach. Tuberculosis (Edinb) 2003; 83:208-12.
41. Marais BJ, Gie RP, Schaaf HS, et al. Childhood pulmonary tuberculosis: old wisdom and new challenges. Am J Respir Crit Care Med 2006; 173:1078-90.
42. Zar HJ, Hanslo D, Apolles P, et al. Induced sputum versus gastric lavage for microbiological confirmation of pulmonary tuberculosis in infants and young children: a prospective study. Lancet 2005; 365:130-4.
43. Chisti MJ, Tebruegge M, La Vincente S, et al. Pneumonia in severely malnourished children in developing countries - mortality risk, aetiology and validity of WHO clinical signs: a systematic review. Trop Med Int Health 2009; 14:1173-89.
44. Cegielski JP, McMurray DN. The relationship between malnutrition and tuberculosis: evidence from studies in humans and experimental animals. Int J Tuberc Lung Dis 2004; 8: 286-98.
45. Hesseling AC, Westra AE, Werschkull H, et al. Outcome of HIV infected children with culture confirmed tuberculosis. Arch Dis Child 2005; 90:1171-4.
46. Soeters M, de Vries AM, Kimpen JL, et al. Clinical features and outcome in children admitted to a TB hospital in the Western Cape-the influence of HIV infection and drug resistance. S Afr Med J 2005; 95:602-6.
47. Walters E, Cotton MF, Rabie H, et al. Clinical presentation and outcome of tuberculosis in human immunodeficiency virus infected children on anti-retroviral therapy. BMC Pediatr 2008; 8:1.
48. Orikiiriza J, Bakeera-Kitaka S, Musiime V, et al. The clinical pattern, prevalence, and factors associated with immune reconstitution inflammatory syndrome in Ugandan children. AIDS 2010; 24:2009-17.
49. Zampoli M, Kilborn T, Eley B. Tuberculosis during early antiretroviral-induced immune reconstitution in HIV-infected children. Int J Tuberc Lung Dis 2007; 11:417-23.
50. American Speech-Language-Hearing Association. Guidelines for Audiologic Screening (Guideline). Available at http://www.asha. org/docs/pdf/GL1997-00199.pdf. Accessed March 26, 2013.
51. American Speech-Language-Hearing Association. Audiologic Management of Inidividuals Receiving Cochleotoxic Drug Therapy (Guideline). Available at http://www.asha.org/docs/pdf/GL1994-00003.pdf. Accessed March 26, 2013.
52. American Speech-Language-Hearing Association. Audiologic Screening (Technical Report). Available at http://www.asha.org/docs/pdf/TR1994-00238.pdf. Accessed March 26, 2013.
53. World Health Organization, Geneva, Switzerland. WHO child growth standards: Weight for age. Available at: http://www. who.int/childgrowth/standards/weight_for_age/en/index.html. Accessed March 26, 2013.
54. World Health Organization, United Nations Children's Fund. WHO child growth standards and the identification of severe acute malnutrition in infants and children, 2009. Available at: http://www.who.int/nutrition/publications/severemalnutrition/9789241598163/en/index.html. Accessed March 26, 2013.